Navigation Links
WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering
Date:1/20/2012

LOS ANGELES, Jan. 20, 2012 /PRNewswire/ -- WestPark Capital, Inc. announced the initial closing of a private placement for Arrogene NanoTechnology, Inc. on January 10, 2012.  A total of 500,000 Units, each Unit consisting of one share of common stock and two common stock purchase warrants, were sold, generating gross proceeds of approximately $500,000.  Proceeds from the offering will be used for working capital and research and development related to Arrogene's diagnostic and therapeutic technologies for brain, breast and lung cancer.  WestPark Capital, Inc. acted as placement agent for the offering.

This news release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful.  The offering was made only by Confidential Private Placement Memorandum.  Copies of the Confidential Private Placement Memorandum may be obtained via written request to WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 310, Los Angeles, California 90067.

About WestPark Capital, Inc.

WestPark Capital is a leading investment banking and securities brokerage firm serving the needs of private and public growth companies worldwide.  WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them.  WestPark provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, private placements and corporate finance advisory services.  Additional information about WestPark Capital, Inc. is available at www.wpcapital.com or at info@wpcapital.com. Member: FINRA/SIPC

About Arrogene NanoTechnology, Inc.

Arrogene NanoTechnology is developing a n
'/>"/>

SOURCE WestPark Capital, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. WestPark Capital Announces $2.6 Million IsoRay Offering
2. WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering
3. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 ... Market Research Report on Global and China Lysine ... is a professional and the deep research report ... introduces Lysine basic information including definition, classification specifications, ... as US, Europe , ...
(Date:4/17/2015)... 17, 2015 Inivata, a ... that their presence at the 2015 American Association for Cancer ... co-founder Nitzan Rosenfeld and a poster presentation. ... th - 22 nd . The presentation, ... , forms part of a session on ...
(Date:4/17/2015)... CVS Health Corporation (NYSE: CVS ) ... 1, 2015, at 8:30 a.m. (EDT) with analysts and ... An audio webcast of the conference call will ... the CVS Health website for all interested parties. To ... will be archived and available on the web site ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2
... , DES MOINES, Iowa, Oct. 12 Briggs, a ... reduce operating costs in the home care market, today ... mandated by the Centers for Medicare & Medicaid Services ... proprietary documentation for all OASIS assessment forms as well ...
... 12 The University of Kansas Hospital has deployed ... provide physicians, nurses, and pharmacy staff in its neonatal ... and reference information. , The University of ... specializes in heart disease, cancer treatment and prevention, neurology, ...
Cached Medicine Technology:Regulatory Leader in OASIS Documentation Introduces OASIS-C Products 2University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety 2University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety 3
(Date:4/17/2015)... (PRWEB) April 17, 2015 John Evans, ... Party on the Patio from 2 p.m. to 3 ... located at 1320 Executive Ct. in Pekin, Illinois, serves ... who need some help to maintain their independence. , ... and tropical treats will be served during the luau. ...
(Date:4/17/2015)... Alcohol and Violence , The National Council on ... driving has been the focus of much public and ... between alcohol and crime received less public attention. , ... assault, and their relationship to alcohol have been clearly ... in America were drinking alcohol at the time of ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive ... Wednesday April 15th, the European Parliament joined its voice ... the Armenian Genocide, “paying tribute, on the eve of ... innocent Armenian victims who perished in the Ottoman Empire.” ... for this timely and needed recognition of a tragic ...
(Date:4/17/2015)... Hills, California (PRWEB) April 17, 2015 ... stands above in his new offering of platelet-rich plasma ... Orthopedic Sports Medicine (MOSM) is known for its ... Dr. Meier brings extensive surgical experience lacking in many ... and stem cell treatments are utilized for pain management ...
(Date:4/17/2015)... Fla. (PRWEB) April 17, 2015 Baptist ... Center have signed a partnership agreement designed to transform ... , The institutions have agreed to create a joint ... treatment protocols and translational research. Baptist MD Anderson Cancer ... 2015, providing a single destination for highly coordinated, multidisciplinary ...
Breaking Medicine News(10 mins):Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3
... of menopausal symptoms. However if this is used in// conjunction ... be altered. ,Scientists of Yale School of Medicine in ... medication taken by breast cancer patients may alter the way ... not even aware of the fact that their patients may ...
... people has shown that late sleeping time may lead to glucose ... late in the night, these are the things that may have ... the new issue of Archives of Internal Medicine. For 722 men ... years in the study, the mean sleep hours was 7 hours ...
... of peppermint or cinnamon could make the drivers of motor ... of time makes the drivers of the vehicle angry, fatigued ... in the study under the conditions of three different types ... were added to the air inside the vehicle with the ...
... of having fractures, are often routinely prescribed vitamin D and ... to light the fact that this may not be true. ... fractures in the elderly people. ,The study had looked ... these people were mobile before they had a low trauma ...
... smoking was considered to be a risk factor for ... the neural degeneration more in people suffering from multiple ... of Harvard school of medicine, researchers had been able ... condition of multiple sclerosis. In a study comprising of ...
... University had found out that it is possible to generate ... first does of insulin was given to patient suffering from ... overcame its supply. Moreover, where there is availability of insulin, ... patients. One reason for such is inability of the patient ...
Cached Medicine News:
... is an endoscopic urethral implant for ... Upon implantation, the Tegress™ Implant solution ... in a Dimethyl Sulfoxide (DMSO) carrier ... reinforces the integrity of the urethras ...
... (VZ) test system is intended ... detection of VZ IgG antibody ... indirect fluorescent antibody (IFA) technique. ... confirm a recent infection or ...
... Captia™ Varicella-Zoster Virus (VZV) IgM ... intended for the detection of ... in human serum as an ... primary infection or reactivation. For ...
... Biotech Captia™ Varicella-Zoster Virus (VZV) IgG Enzyme-linked ... detection and quantitative determination of IgG antibody ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
Medicine Products: